Notícias Dor Biopharma - DOR | Ações American Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
AMEX
Dor Biopharma (DOR)
Dor Biopharma (DOR) Notícias

Dor Biopharma (DOR)

0,00

0,00

(0,00%)

Fechado 24 Março 5:00PM

Atrasado por 15 minutos

0,00

0,00

(0,00%)

Após o horário de negociação: -

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

DOR BioPharma Announces Advances in Mucosal Vaccines for Botulinum Toxin; Antigens are Made Using Dowpharma's Pfenex Expression

DOR BioPharma Announces Private Equity Financing of $3.65 Million with Institutional Investors

DOR BioPharma Reports Year End 2005 Financial Results and Accomplishments; DOR Provides Guidance on Regulatory Filings on orBec

DOR BioPharma Provides Financial Guidance and Update on European Regulatory Plans for orBec(R)

DOR BioPharma Announces Positive Phase I Results of RiVax(TM), its Vaccine Against Ricin Toxin; Vaccine is Immunogenic and Well

DOR BioPharma Achieves Manufacturing Milestone in Development of RiVax(TM); DOR and Its Collaborators Achieve 2nd Milestone Ahea

DOR BioPharma Reports Positive New Survival Findings from Previously Completed Phase II and III Clinical Trials of orBec(R); Res

DOR BioPharma Secures $6 Million Equity Commitment from Fusion Capital

DOR BioPharma Plans FDA NDA and European MAA Filing Strategy for orBec

DOR BioPharma Inc. Reports Third Quarter 2005 Financial Results and Reviews Recent Achievements; Conference Call Scheduled for N

DOR BioPharma to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference

DOR BioPharma Executes Letter of Intent for Acquisition of Gastrotech Pharma; Acquisition Bolsters Biotherapeutics Pipeline

DOR BioPharma Receives Notice of Delisting from American Stock Exchange; Company to Continue to Negotiate Potential Compliance-A

DOR BioPharma Provides Update on Programs and Corporate Matters

Dr. Chris Dale, Vice President, Technology, Cambrex Biopharmaceuticals and Dr. Robert N. Brey, Chief Scientific Officer, DOR Bio

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições